Nattokinase Encapsulated Nanomedicine for Targeted Thrombolysis: Development, Improved in Vivo Thrombolytic Effects, and Ultrasound/Photoacoustic Imaging
Molecular Pharmaceutics · 01.01.2024 · 21 (1) · 283-302
DOI: 10.1021/acs.molpharmaceut.3c00830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 21.12.2023. Verfasst von Vishnu Priya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi 221005, U.P., India. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Photoacoustic Techniques. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Indian Council of Medical Research, Indian Institute of Technology (BHU) Varanasi, Ministry of Education, India.
Abstract (Originalsprache)
Nattokinase (NK), a potent thrombolytic enzyme that dissolves blood clots, is highly used in the treatment of cardiovascular disorders. However, its effective delivery remains demanding because of stability and bioavailability problems owing to its high molecular weight and proteineous nature. In this research, we have developed novel NK-loaded nontargeted liposomes (NK-LS) and targeted liposomes (RGD-NK-LS and AM-NK-LS) by the reverse phase evaporation method. The physiochemical characterizations (particle size, polydispersity index, zeta potential, and morphology) were performed by a Zetasizer, SEM, TEM, and AFM. The Bradford assay and XPS analysis confirmed the successful surface conjugation of the targeting ligands. Platelet interaction studies by CLSM, photon imager optima, and flow cytometry showed significantly higher (P < 0.05) platelet binding affinity of targeted liposomes. In vitro evaluations were performed using human blood and a fibrinolysis study by CLSM imaging demonstrating the potent antithrombotic efficacy of AM-NK-LS. Furthermore, bleeding and clotting time studies revealed that the targeted liposomes were free from any bleeding complications. Moreover, the in vivo FeCl3 model on Sprague-Dawley (SD) rats using a Doppler flow meter and ultrasound/photoacoustic imaging indicated the increased % thrombolysis and potent affinity of targeted liposomes toward the thrombus site. Additionally, in vitro hemocompatibility and histopathology studies demonstrated the safety and biocompatibility of the nanoformulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering and Technology, IIT (BHU), Varanasi 221005, U.P., India.
- Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, U.P., India.
ORCID-Profile: Madaswamy S Muthu
Förderung
- Indian Council of Medical Research
- Indian Institute of Technology (BHU) Varanasi
- Ministry of Education, India
Zitieren
APA
Priya, V., Samridhi, Singh, N., Dash, D., & Muthu, M. S. (2024). Nattokinase Encapsulated Nanomedicine for Targeted Thrombolysis: Development, Improved in Vivo Thrombolytic Effects, and Ultrasound/Photoacoustic Imaging. Molecular Pharmaceutics, 21(1), 283-302. https://doi.org/10.1021/acs.molpharmaceut.3c00830
Vancouver
Priya V, Samridhi, Singh N, Dash D, Muthu MS. Nattokinase Encapsulated Nanomedicine for Targeted Thrombolysis: Development, Improved in Vivo Thrombolytic Effects, and Ultrasound/Photoacoustic Imaging. Molecular Pharmaceutics. 2024;21(1):283-302. doi:10.1021/acs.molpharmaceut.3c00830
BibTeX
@article{Priya2024,
author = {Priya, Vishnu and Samridhi and Singh, Nitesh and Dash, Debabrata and Muthu, Madaswamy S},
title = {Nattokinase Encapsulated Nanomedicine for Targeted Thrombolysis: Development, Improved in Vivo Thrombolytic Effects, and Ultrasound/Photoacoustic Imaging},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {1},
pages = {283--302},
doi = {10.1021/acs.molpharmaceut.3c00830}
}
EUVIMED